Metaanalyses have demonstrated a linear relationship between level of blood pressure (BP) and risk for cardiovascular events. The prevalence of resistant hypertension in the general population is unknown and vary in the range of 1,9 to 30%. More established approaches, such as low dietary salt and mineralocorticoid receptor blockers are indicated for these patients. New technologies, such as renal denervation and carotid stimulation, may be used in the management of patients with resistant hypertension.
A.K. Zhanatbekova Semey State Medical University, Kazakhstan Department of internship by therapy
1. Pantelis A. Sarafidis, George L. Bakris. Resistant Hypertension An Overview of Evaluation and Treatment. JACC Vol. 52, No. 22, 2008:1749–57. 2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206 –52. 3. 2013 ESH/ESC Guidelines for the management of arterial hypertension. 4. Maria Lorenza Muiesan, Massimo Salvetti, Dam-iano Rizzoni, Anna Paini, Claudia Agabiti-Rosei, Carlo Ag-giusti and Enrico Agabiti Rosei. Resistant hypertension and target organ damage. Hypert Research (2013) 36, 485–491. 5. 6. Anthony J. Viera. Resistant Hypertension. J Am Board Fam Pract July–August 2012 Vol. 25 No. 4. 7. Brambilla G et al. Prevalence and clinical char-acteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013 Oct; 31(10):2018-24. 8. Wenjun Ma, Yuqing Zhang. Low rate of resistant hypertension in Chinese patients with hypertension: an analysis of the HOT-CHINA study. J Hypertens. 2013, 31:2386–2390. 9. Tetsuo N, Masao O, Jun S and Yoko M. The possibility of resistant hypertension during the treatment of hypertensive patients. Hypertens Researh 2013, 36, 924–929. 10. Kotseva K, Wood D, De Backer G et al. Cardio-vascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929–940 (2009). 11. J. P. Garg, W. J. Elliott, A. Folker, M. Izhar, and H. R. Black. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypert, vol. 18, no. 5, pp. 619–626, 2005. 12. Anastasios Makris, Maria Seferou, Dimitris P. Papadopoulos Resistant Hypertension Workup and Approach to Treatment. Int J Hypertens. Volume 2011. 13. Selçuk Şen, Soner Sabırlı, Tolga Özyiğit and Yağız Üresin. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. TherapAdvChrDis (2013) 4(5) 232–241. 14. Yukai Liu, Ken Chen, Xun Kou, Yu Han, Lin Zhou, Chunyu Zeng. Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials. PLOS ONE July 2013 | Volume 8 | Issue 7 | e7011. 15. Eric Judd and Edgar A Jaimes. Aliskiren, am-lodipine and hydrochlorothiazide triple combination for hypertension. Expert Review of Cardiovascular Therapy. March 2012, Vol. 10, No. 3, Pages 293-303 , 16. McMurray J., Abraham, W., Dickstein, K., Køber, L., Massie, B. and Krum, H. (2012) Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 14: 341–343. 17. Parving, H., Brenner, B., McMurray, J., Zeeuw, D., Haffner, S., Solomon, S. et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24(2009): 1663–1671. 18. Alberto Polimeni; Antonio Curcio; Ciro Indolfi. Renal Sympathetic Denervation for Treating Resistant Hypertension Circulation Journal Vol.77, April 2013 19. Panagiotis Kougias, Sarah M. Weakley, Qizhi Yao, Peter H. Lin, and Changyi Chen. Arterial baroreceptors in the management of systemic Hypertension. Med Sci Monit. PMC 2010 August 13.
: 20